MindBio Therapeutics Corp. Reports Six Month Sustained Antidepressant Response in Clinical Trials. 72% reduction in Depression Severity Recorded.Dear ,We are excited to share significant progress in our mission to transform mental health treatments....

Hi We are thrilled to share some significant progress from our ongoing Phase 2B clinical trial focused on advanced-stage cancer patients experiencing symptoms of anxiety, depression and existential distress. In this Phase 2B study, 40 participants ar...

Hi MindBio is pleased to report it has completed its 6-month milestone post treatment with MB22001 in a Phase 2A microdosing depression trial and will be releasing the data in the coming fortnight.Photo: Justin Hanka, MindBio CEO and Co-Founder insp...

Hi MindBio is pleased to report on long term stability data for its lead candidate drug MB22001. These stability findings, are an important part of our commercialisation journey, to produce medicines that can be stored and used safely for long perio...

Hi Join me as I discuss MindBio's landmark take-home microdosing clinical trial in patients with Major Depressive Disorder as we enter our 25th participant into this randomized, triple blind, double dummy, active placebo controlled trial.Click to Wat...

Dr Rachael Sumner discusses Microdosing MB22001 for negative mood symptom relief in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Here is the link to the clinical trial paper on Sleep produced by MindBio scientific collaborators and published in Nature’s portfolio journal Translational Psychiatry:https://www.nature.com/articles/s41398-024-02900-4

Unlocking Market Potential: Leveraging Big Data Analytics to Revolutionize Depression Research

MindBio publishes positive Phase 2a Data in Landmark Depression Trial

Positive Phase 2a results reported in Depression trial. Permalink